Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will include 120 participants aged 8 and up with Duchenne, Becker, or autosomal recessive limb-girdle (specifically: LGMD 2C-2F and 2I) muscular dystrophies that have no clinical cardiac symptoms. Participants will be randomized to one of four arms: Arm 1 CoQ10 alone, Arm 2 Lisinopril alone, Arm 3 CoQ10 and Lisinopril or Arm 4 No study medication. Randomization will be stratified by ambulatory status and corticosteroid use. The primary outcome for the study is the myocardial performance index (MPI), measured by standard Doppler echocardiography. The study will last 24 months with visits at Months 0.5,1.5, 6, 12, 18 and 24.

Following completion of the Clinical Trial of Coenzyme Q10 and Lisinopril, participants will be offered participation in a companion protocol: PITT1215 A Natural History Companion Study to PITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies. The objective of this study is to evaluate the longitudinal natural history of DMD, BMD, and LGMD2I and to evaluate the effects of Coenzyme Q10 and/or Lisinopril on prevention of cardiac dysfunction in these disorders.This will be an 18-month longitudinal natural history study designed to accompany the Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cooperative International Neuromuscular Research Group
• Collaborator: United States Department of Defense
• Treatments: Coenzyme Q10; Lisinopril; Ubiquinone

Criteria

Inclusion Criteria:

• 8 years of age or older

• Confirmed genetic diagnosis of Duchenne, Becker, or Limb Girdle muscular dystrophy

• Beta-blocker naïve

• Screening Doppler echocardiographic MPI measurement greater than or equal to 0.40 for the highest MPI value (spectral and tissue) or circumferential strain measured by STE that is less negative than or equal to - 23

• Normal left ventricular fractional shortening (≥28%) and no clinical cardiac symptoms

• Has not participated in other therapeutic research protocol within the last 6 months prior to screening

• Ability to swallow tablets

Exclusion Criteria:

• Spine curvature greater than 30% (based on the x-ray performed at screening)

• History of significant concomitant illness or significant impairment of renal or hepatic function

• History of hypersensitivity to ACE inhibitors

• History of idiopathic or hereditary angioedema or a history of angioedema with prior ACE inhibitor use

• Use of carnitine, creatine, glutamine, or any herbal medicines (this would not include herbal teas unless they are consumed daily with intended medicinal effect) in the 3-months prior to enrollment

• CoQ10 and/or ACE inhibitor use for a duration greater than 6 months

• CoQ10 and/or ACE inhibitor use in the 3-months prior to enrollment

• CoQ10 serum level of 2.5 ug/ml or higher

• Investigator assessment of inability to comply with protocol